The National Center for Cancer Immune Therapy (CCIT-DK)
CCIT-DK has a focus on development of immunological
treatment of cancer, and has a research profile based on equally
weighted experimental and clinical projects facilitating quick clinical
implementation of new immunotherapies e.g. anti-CTLA4. It is the
European leading centre for use of tumour infiltrating lymphocytes (TIL)
for adoptive T-cell therapy (ACT) for metastatic melanoma. CCIT-DK
provides the infrastructure of certified clinical grade laboratory for
preparation of therapeutic cellular products and evaluations of immune
The laboratory has extensive experience in production
of both T-cells and DCs (including mRNA transfection) for clinical use.
We also perform characterization of tumour antigens recognized by T
cells, studies of T cell and dendritic cell (DC) biology and
interactions, and biological monitoring of immune therapies of cancer,
e.g. vaccination/DC trials and ACT.
Link to the homepage of CCIT - DK